Jackfruit Effects on Adipokines and Cognition in Boxers

Effect of Jackfruit Consumption on Adipokine, Cerebral Response, Cognitive Performance and Anthropometric Parameters in Boxers

This study investigates the effects of jackfruit oil extract on adipokine levels (Irisin, Omentin-1), brain-derived neurotrophic factor (BDNF), cognitive performance, and body measurements in healthy young boxers aged 18-25. Participants were randomly assigned to four groups receiving different doses of jackfruit oil extract (0, 100, 200, 300 mg/kg) or no supplement. Saliva samples, cognitive tests, and body measurements were collected at the start of the study and after 30 days to evaluate the outcomes.

Study Overview

• Status: Completed
• Conditions: Cognitive Function; Irisin; Exercise Physiology; Adipokine Response; Brain-Derived Neurotrophic Factor (BDNF); Omentin-1
• Intervention / Treatment: Dietary supplement: Jackfruit Supplement

Detailed Description

This interventional study evaluates the effects of different doses of jackfruit oil extract on healthy young boxers aged 18-25. Participants were randomly assigned to four groups and followed for 30 days.

Saliva samples were collected to measure irisin, omentin-1, and BDNF levels. Cognitive performance was assessed using the Wisconsin Card Sorting Test and the Trail Making Test. Anthropometric parameters including weight, BMI, waist, hip, chest, limb circumferences, and body composition were measured at baseline and on day 30.

Statistical analyses were performed using SPSS version 26. ANOVA, Duncan, and Pearson correlation tests were used to determine significant differences and relationships between variables.

This study is randomized and controlled. Participants receive either one of three doses of jackfruit oil extract or no supplement. The follow-up period is 30 days.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey (Türkiye)
  • Merkez
    • Bayburt, Merkez, Turkey (Türkiye), 69000
      • Bayburt Gençlik Merkezi Kapali Spor Salonu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male boxers aged 18-25 years
• Healthy individuals without any diagnosed chronic disease
• Participating in regular weekly boxing training
• Able to continue training throughout the study period
• Willing to voluntarily participate in the study
• Able to provide written and/or verbal informed consent

Exclusion Criteria:

• Presence of chronic diseases (e.g., diabetes, cardiovascular disorders)
• Any injury or musculoskeletal condition preventing continuation of training
• Known allergy or hypersensitivity to jackfruit or its components
• Use of medications or supplements that could interfere with study outcomes
• Individuals who refuse to provide informed consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: J0 - Kontrol Grubu; Katılımcılar hiçbir jackfruit yağı ekstresi almadı. Sadece normal diyet ve antrenman programlarını sürdürdüler.
Experimental: J100; Katılımcılara 100 mg/kg jackfruit yağı ekstresi oral olarak 500 ml su içinde verildi. Müdahale 30 gün boyunca günlük olarak uygulandı.	Dietary supplement: Jackfruit Supplement; Participants in the experimental group will receive a daily dose of jackfruit supplement during the study period. The supplement is administered orally and standardized for bioactive components. Participants in the control group will not receive any jackfruit supplement.
Experimental: J200; Katılımcılara 200 mg/kg jackfruit yağı ekstresi oral olarak 500 ml su içinde verildi. Müdahale 30 gün boyunca günlük olarak uygulandı.	Dietary supplement: Jackfruit Supplement; Participants in the experimental group will receive a daily dose of jackfruit supplement during the study period. The supplement is administered orally and standardized for bioactive components. Participants in the control group will not receive any jackfruit supplement.
Experimental: J300; Katılımcılara 300 mg/kg jackfruit yağı ekstresi oral olarak 500 ml su içinde verildi. Müdahale 30 gün boyunca günlük olarak uygulandı.	Dietary supplement: Jackfruit Supplement; Participants in the experimental group will receive a daily dose of jackfruit supplement during the study period. The supplement is administered orally and standardized for bioactive components. Participants in the control group will not receive any jackfruit supplement.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Salivary Irisin Level	Irisin levels measured from saliva samples collected from participants using the ELISA method.	Day 0 and Day 30
Salivary Omentin-1 Level	Omentin-1 levels measured from saliva samples collected from participants using the ELISA method.	Day 0 and Day 30.
Salivary BDNF Level	BDNF levels measured from saliva samples collected from participants using the ELISA method.	Day 0 and Day 30.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Body Weight (kg)	Body weight measured using Tanita BC-418 bioimpedance device.	Day 0 and Day 30
Height (cm)	Height measured using a standard stadiometer.	Day 0 and Day 30
Body Mass Index (kg/m²)	BMI calculated using the formula weight (kg)/height (m²).	Day 0 and Day 30
Waist Circumference (cm)	Waist circumference measured with a flexible tape measure.	Day 0 and Day 30
Hip Circumference (cm)	Hip circumference measured with a flexible tape measure.	Day 0 and Day 30
Chest Circumference (cm)	Chest circumference measured using a flexible tape measure.	Day 0 and Day 30
Upper Arm Circumference (Right/Left, cm)	Right and left upper arm circumferences measured with a flexible tape measure.	Day 0 and Day 30
Wrist Circumference (Right/Left, cm)	Right and left wrist circumferences measured with a flexible tape measure.	Day 0 and Day 30
Thigh Circumference (Right/Left, cm)	Right and left thigh circumferences measured with a flexible tape measure.	Day 0 and Day 30
Calf Circumference (Right/Left, cm)	Right and left calf circumferences measured with a flexible tape measure.	Day 0 and Day 30
Total Body Fat Mass (kg)	Total body fat mass measured using Tanita BC-418.	Day 0 and Day 30
Total Body Fat Percentage (%)	Total body fat percentage measured using Tanita BC-418.	Day 0 and Day 30
Abdominal Fat Mass (kg)	Abdominal fat mass measured using Tanita BC-418.	Day 0 and Day 30
Regional Fat Percentages (Right/Left Arm & Leg)	Regional fat percentages for arms and legs measured by Tanita BC-418.	Day 0 and Day 30
Total Muscle Mass (kg)	Total muscle mass assessed using Tanita BC-418.	Day 0 and Day 30
Regional Muscle Mass (Right/Left Arm & Leg, kg)	Regional muscle mass of arms and legs measured by Tanita BC-418.	Day 0 and Day 30
Basal Metabolic Rate (BMR)	Basal metabolic rate calculated by Tanita BC-418.	Day 0 and Day 30
Metabolic Age	Metabolic age estimated using Tanita BC-418 device.	Day 0 and Day 30
Total Body Water (kg)	Total body water measured via bioimpedance analysis.	Day 0 and Day 30
Total Body Water Percentage (%)	Total Body Water Percentage (%)	Day 0 and Day 30
WCST Total Correct Responses	Total correct responses obtained from the Wisconsin Card Sorting Test.	Day 0 and Day 30
WCST Total Incorrect Responses	Total incorrect responses measured using the Wisconsin Card Sorting Test.	Day 0 and Day 30
WCST Perseverative Error Count	Perseverative errors recorded during the Wisconsin Card Sorting Test.	Day 0 and Day 30
WCST Total Time (seconds)	Total time required to complete the Wisconsin Card Sorting Test.	Day 0 and Day 30
Trail Making Test A Completion Time (seconds)	Completion time for Trail Making Test Part A.	Day 0 and Day 30
Trail Making Test B Completion Time (seconds)	Completion time for Trail Making Test Part B.	Day 0 and Day 30
Biomarker Correlations (Irisin-Omentin-BDNF vs. Dose/Day)	Pearson correlation analysis examining relationships between biomarkers and intervention dose/day.	Based on Day 30 measurements
Safety Outcomes (Adverse Event Monitoring)	Monitoring of potential adverse events related to 300 mg/kg JOE administration.	Continuous monitoring throughout 30 days

Collaborators and Investigators

• Sponsor: Bayburt University
• Investigators: Principal Investigator: BÜLENT BAYRAKTAR, BAYBURT ÜNİVERSİTESİ

Publications and helpful links

Helpful Links

• This study investigates the effects of jackfruit consumption on adipokine levels (irisin, omentin-1), brain-derived neurotrophic factor (BDNF), cognitive performance, and anthropometric parameters in young boxers aged 18-25.

Study record dates

Study Major Dates

• Study Start (Actual): January 7, 2025
• Primary Completion (Actual): February 10, 2025
• Study Completion (Actual): June 10, 2025

Study Registration Dates

• First Submitted: August 26, 2025
• First Submitted That Met QC Criteria: December 4, 2025
• First Posted (Actual): December 8, 2025

Study Record Updates

• Last Update Posted (Actual): December 8, 2025
• Last Update Submitted That Met QC Criteria: December 4, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Body Composition; Adipokines; BDNF; Irisin; Athletes; Cognitive Performance; Trail Making Test; Anthropometric Measurements; Boxer; Jackfruit; Omentin-1; Wisconsin Card Sorting Test (WCST)
• Other Study ID Numbers: BU-2025-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified participant-level data including salivary irisin, omentin-1, BDNF levels, anthropometric measurements, and cognitive test results will be shared with other researchers upon reasonable request after publication of the main study results. Access will require approval from the institutional ethics committee and signing a data use agreement.
• IPD Sharing Time Frame: De-identified participant-level data and supporting documents will be available to other researchers starting after publication of the main study results and will remain accessible for 5 years following publication.
• IPD Sharing Access Criteria: "Access to de-identified participant-level data and supporting documents will be granted to qualified researchers for legitimate scientific purposes. Researchers must submit a request detailing their research objectives and methods, obtain approval from the institutional ethics committee, and sign a data use agreement. Approved researchers will receive access to the specified datasets and supporting materials electronically.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ANALYTIC_CODE

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No